A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in children and adults

Trial Profile

A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in children and adults

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs TCR alphabeta-CD19-depleted peripheral blood stem cell therapy (Primary)
  • Indications Cancer; Haematological malignancies; Metabolic disorders; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Miltenyi Biotec GmbH
  • Most Recent Events

    • 06 Dec 2016 Results (n=30) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 26 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top